Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGD014 in HIV-Infected Individuals on Suppressive ART
NCT03570918Phase 1Completed
- Sponsor
- MacroGenics
- Start
- Sep 2018
- Primary completion
- Sep 2021
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MGD014 in human immunodeficiency virus type 1 infection (HIV-1) (9 arms), sponsored by MacroGenics. Primary endpoint: Number of Participants With Treatment-Emerging Adverse Events up to 77 days. Started Sep 2018; status: completed.
02
Drugs
MGD014
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03570918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03570918.